期刊文献+

E1A基因对喉癌细胞系放射敏感性的影响及机制的初步实验研究 被引量:1

Effect of E1A gene on radiosensitivity of human laryngeal carcinoma cells and its correlated mechanisms
原文传递
导出
摘要 目的探讨E1A基因对喉癌细胞系(Hep-2细胞)放射敏感性的影响并初步探讨其机制。方法以腺病毒为载体将E1A基因及其空载体转染至人Hep-2细胞,经RT—PCR法鉴定获得含E1A的阳性克隆。设未转染组(PBS)、转染空载体组(Ad—β—gal)和转染组(Ad—E1A),分别给予6MVx线单次照射0、1、2、4、6、8、10Gy,成克隆实验绘制细胞存活曲线并计算D0、Dq、α、β值以观察E1A基因对Hep-2细胞放射敏感性的影响。设PBS组、Ad—B—gal组、Ad—E1A组、PBS+照射组、Ad—β—gal+照射组、Ad-E1A+照射组,单次照射6Gy,流式细胞仪检测细胞凋亡及RT-PCR检测血管内皮生长因子(VEGF)水平并半定量VEGF以初步探讨机制。结果转染后的阳性克隆细胞RT—PCR结果显示E1A已整合到细胞基因组中并且稳定表达。Ad—E1A组、Ad—β—gal组、PBS组细胞的D0值分别为0.86、1.96、1.98Gy,Dq值分别为1.02、1.97、1.99Gy,d值分别为0.536、0.112、0.104(Gy^-1)和13值分别为0.521、0.137、0.125(Gy^-2)。、PBS组、Ad-β-gal组、Ad-E1A组、PBS+照射组、Ad-β-gal+照射组、AdE1A+照射组的细胞凋亡率分别为1.26%、1.18%、2.16%、2.55%、2.96%、4.96%。Ad-E1A组、PBS+照射组、Ad-β-gal+照射组及Ad-E1A+照射组VEGF的表达水平较PBS组及Ad—β—gal组低,且Ad-E1A+照射组表达最低。结论成功构建了稳定表达E1A基因的喉癌细胞系。E1A基因对人喉癌细胞有放射增敏作用,其机制可能与降低VEGF表达和促进细胞凋亡有关。 Objective To investigate the effect of El A gene on the radiosensitivity of human laryngeal carcinoma cells and its correlated mechanisms. Methods The Ad-E1A and Ad-β-gal were amplificated in Hek293 cells, extracted by freezing( -80℃ ) and thawing( 37℃) repeatedly (3 times) , purificated by the method of density gradient of CsCI and titrated by plaque assay method. Then they were transfected into human laryngeal carcinoma cells ( Hep-2 ) and authenticated by RT-PCR. The radiosensitivity of Hep-2 cells transfected with or without E1A were studied by cell surviral curve. Finally we investigated the correlated mechanisms including cell apoptosis studied by flow cytometry and VEGF content studied by RT-PCR. Resuits The radiosensitivity of Hep-2 cells transfected with E1A was intensified, Do and Dq were lowered and α was increased. Flow cytometry showed that the apoptosis rate of cells with E1A or with E1A and radiotherapy was increased. The VEGF content of the cells transfected with E1 A or treated by radiotherapy was decreased, which reached the lowest level when the cells were treated with the both mathods. Conclusions E1A gene can intensify the radiosensitivity and contribute to the apoptosis of human laryngeal carcinoma ceils. E1A gene and radiotherapy can markedly decrease the VEGF content.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2008年第6期467-469,共3页 Chinese Journal of Radiation Oncology
基金 湖南省自然科学基金资助(05JJ4008)
关键词 细胞系 肿瘤 放射敏感性 E1A基因 血管内皮生长因子 Cell line,tumor Radiosensitivity E1A gene Vascular endothelial growth factor
  • 相关文献

参考文献8

  • 1Frisch SM. Antioncogenic effect of adenovincs EIA in human tumer cells. Pr℃ Natl Acad Sci USA,1991,88:177-178.
  • 2Muschel RJ, Soto ED, Mckenna WG, et al. Radiosensitization and apoptosis. Oncogene, 1998,17:3359-3363.
  • 3Weichselbaum RR,Hallahan DE,Bechett MA,et al. Gene therapy targeted by radiation preferentially radiosenstitizes tumor cells. Cancer Res, 1994,54:4266.
  • 4Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1 A-mediated paclitaxel sensitization in Her2/neu-overexpressing ovarian cancer skov3, ipl through apoptosis involving the caspase-3 pathway. Clin Cancer Res ,2000,16:250-259.
  • 5Zips D, Krause M, Hessel F,et al. Experimental study on different combination schedules of VEGF-receptor inhibitor FFK 787/ZK 222584 and fractionated irradiation. Anticancer Res, 2003,23 (5A) :3869-3876.
  • 6McDonnell CO, Holden G,Sheridan ME,et al. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res ,2004 ,116 :19-23.
  • 7Zhou ZC, Zhou RR, Guan H, et al. E1 A gene therapy inhibits angiagenesis in a Ewing's sarcoma animal model Mol. Cancer Therapeutics,2003,2 : 1313-1319.
  • 8Jia SF,Zhou Z. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther,2002, 9:407-413.

同被引文献8

  • 1Liu X, Marmorstein R. Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev,2007,21 : 2711-2716.
  • 2Zhou RR, Jia SF, Zhou Z, et al. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther,2002 ,9 :407-413.
  • 3Itamochi H, Kigawa I, Kanamori Y, et al. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma:a potential treatment strategy. Mol Cancer Ther,2007 ,6 :227-235.
  • 4Bartholomeusz C, Itamochi H, Nitta M, et al. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene,2006 ,25 :79-90.
  • 5Sanchez PR, Lieonart M, Cajal SR. Lack of correlation between p53 protein level and sensitivity of DNA-damaging agents in keratinocytes carrying adenovirus E1A mutants. Oncogene, 2005,11 : 675-682.
  • 6Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the eytotoxieity of anticancer agents. Cell, 2003,74 : 957 -967.
  • 7Chougule PB, Akhtar MS, Akerley W, et al. Chemoradiotherapy for advanced inoperable head and neck cancer: a phase Ⅱ study. Semin Radiat Oncol ,2004,9:58-63.
  • 8张大昕,赵清正,余子豪.E1A与凋亡的关系及其对肿瘤放射敏感性的影响[J].中华放射肿瘤学杂志,2000,9(1):64-66. 被引量:1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部